NEW PERSPECTIVES OF DIPYRIDAMOL USAGE IN TREATMENT OF CORONARY HEART DISEASE
Abstract
There is a great number of coronary patients to whom traditional methods of myocardium revascularization are not indicated. Addition of dipyridamol to traditional antianginal treatment promotes improvement of clinical features of the disease and decreased functional class of angina in coronary patients. The usage of dipyridamol for 3 months was accompanied by increased physical stress tolerance threshold, increased time of physical stress, decreased asynergy areas on echo ate peak stress, suggesting possible angiogenesis in myocardium hypoperfusion areas in the region of stenotic coronary artery.
About the Authors
Y. I. Buziashvili
Научный центр сердечно-сосудистой хирургии имени А.Н. Бакулева
Russian Federation
Russian Federation
S. T. Matskeplishvili
Научный центр сердечно-сосудистой хирургии имени А.Н. Бакулева
Russian Federation
Russian Federation
E. U. Asymbekova
Научный центр сердечно-сосудистой хирургии имени А.Н. Бакулева
Russian Federation
Russian Federation
I. H. Hapiy
Научный центр сердечно-сосудистой хирургии имени А.Н. Бакулева
Russian Federation
Russian Federation
T. V. Burduli
Научный центр сердечно-сосудистой хирургии имени А.Н. Бакулева
Russian Federation
Russian Federation
O. S. Sherbakova
Научный центр сердечно-сосудистой хирургии имени А.Н. Бакулева
Russian Federation
Russian Federation
V. I. Buvaltsev
Научный центр сердечно-сосудистой хирургии имени А.Н. Бакулева
Russian Federation
Russian Federation
References
1. Бузиашвили Ю.И., Picano Е., Амбатьелло С.Г., Мацкеплишвили С.Т. Ангиогенез как антиишемический механизм. Кардиология 2000; 12: 82-86.
2. Гуревич К.Г., Лобанова Е.Г. Биохимическая фармакология дипиридамола, клиническое применение. Кардиология. 2000; 12: С. 87-91.
3. Николенко Е.Я., Корж А.Н., Лурье С.З. Применение курантила для коррекции реологических нарушений у больных с хронической сердечной недостаточностью. Укр. мед. вестник. 2000; 2 (16) III/IV: 41-47.
4. A randomized, double blind, placebo-controlled, parallel group study E. Picano, on behalf of the PISA (Persantin in Stable Angina) study group. Dipyridamole in chronic stable angina pectoris. Eur. Heart J. 2001; 22: 1785-1793.
5. Belardinelli R., Belardinelli L., Schryock J.C. Effects of dipyridamole on coronary colfaterization and myocardial perfusion in patients with ischemic cardiomyopathy. Eur. Heart. J. 2001; 22: 1205-1213.
6. Castello R., Hidalgo R. Dipyridamole-induced myocardiak ischemia (letter). J. Am. Med. Assoс. 1988; 259: 1179.
7. Couffinhal T., et al. Vascular endothelial growth factor/vasclular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am.J. Pathol. 1997; 150: 5: 1673-1685.
8. Cuevas P., et al. Protection of rat myocardium by mitogenic and non-mitogenic fibroblast growth factor during post-ischemic reperfusion. Growth Factors 1997; 15: 29-40.
9. DiSalvo T.G., Webster MWI, Chesebro J.H., Fuster V. Dipyridamole. In: Cardiovascular Drug Therapy. Messerii FH (ed). WB Saunders Co., Philadelphia; 1998. pp. 1451-1464.
10. Fisher S., Sharma H.S., Karliczek G.F., Schaper W. Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Mol. Brain. Res. 1995; 28: 141-148.
11. Hashimoto E., Kage K., Ogita T., Nakaoka T., Matsuoka R., Kira Y. Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. Biochem. Biophys. Res. Commun. 1994; 204: 318-324.
12. Keitz T.N., Innerfield M., Gitler В., Cooper J.A. Dipyridamole-induced myocardiak ischemia. J. Am. Med. Assoс. 1987; 257; 1515-1516.
13. Castello R., Hidalgo R. Dipyridamole-induced myocardiak ischemia (letter). J. Am. Med. Assoс. 1988; 259: 1179.
14. Mall G., Schikora I., Mattfeldt T., Bodle R. Dipyridamole-induced neoformation of capillaries in the rat heart. Lab. Invest. 1987; 57: 86-93.
15. Memmger C.J., Granger H.J. Mechanisms leading to adenosine-stimulated proliferation of microvascular endothelial cells. Am. J. Physiol. 1990; 258: H198-H206.
16. Picano E., Michelassi C. Chronic oral dipyridamole as a «novel» antianginal drug: the collateral hypothesis. Cardiovasc. Res. 1997; 33: 666-670.
17. Sacks H.S., Ancona-Berk V.A., Berrier J., Nagalingam R., Chalmers T.C. Dipyridamole in the treatment of angina pectoris: a meta-analysis. Clin. Pharmacol. Ther. 1988; 43: 610-615.
18. Sasayama S., et al. Recent insights into coronary collateral circulation. Circulation. 1992 Mar; 85(3): 1197-204.
19. Schaper W. Collateral vessel growth in the human heart. Role of fibroblast growth facor-2. Circulation 1996; 94: 600-601.
20. Sueishi K., et al. Atherosclerosis and angiogenesis. Its pathophysiological significance in humane as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Ann. N.Y. Acad. Sci. 1997 Apr 15; 811: 311-22; 322-4.
21. Torning G. Capillary neoformation in the heart and skeletal muscle during dipyridamole-treatment and exercise. Acta Pathol. Miicrobiol. Immunol. Scand. 1982, 72: 369-770.
Review
For citations:
Buziashvili Y.I., Matskeplishvili S.T., Asymbekova E.U., Hapiy I.H., Burduli T.V., Sherbakova O.S., Buvaltsev V.I. NEW PERSPECTIVES OF DIPYRIDAMOL USAGE IN TREATMENT OF CORONARY HEART DISEASE. Russian Journal of Cardiology. 2003;(4):67-71. (In Russ.)
Views:
505
Email this article 